S. Mckeown
Cancer Research · 2014
A researcher in the Science corpus: 1 paper; trusts 8 researchers and is trusted by 5 researchers here, as inferred from the citation graph.
Subfields
- Cancer Research — 19 citations into it; #451 of 1,780 by trust here, #1,703 by citations
- Molecular Biology — 13 citations into it
- Biotechnology — 7 citations into it
Whom S. Mckeown trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts S. Mckeown overall
Papers from S. Mckeown's perspective
Ordered by how strongly the researchers S. Mckeown trusts endorse each paper. Same corpus, a different order for every researcher.
- Targeting HIF-1 for cancer therapy (Nature Reviews. Cancer)
- Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. (Journal of the National Cancer Institute)
- Hypoxia — a key regulatory factor in tumour growth (Nature Reviews. Cancer)
- Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. (Radiotherapy and Oncology)
- Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. (Cell Metabolism)
- Why do cancers have high aerobic glycolysis? (Nature Reviews. Cancer)
- Hallmarks of cancer: the next generation. (Cell)
- Lysyl oxidase is essential for hypoxia-induced metastasis (Nature)
- HIF-1 as a target for drug development (Nature reviews. Drug discovery)
- Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. (Journal of Clinical Investigation)
Their papers
- Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response. (2014) — 922 citations